This is the first study to demonstrate a consistent and profound elevation of plasma PTX3 levels in NASH patients whose diagnosis was based on results of liver biopsy, the gold standard for the diagnosis of NASH. Here, PTX3 is linked to metabolic dysfunction-associated steatohepatitis.